{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-136042","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.865816+00:00","generated_at":"2026-05-29T03:41:50.622246+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors","bullets":["Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.","Granted option to purchase 44,200 shares vesting monthly over 36 months; annual director fee of $40,000.","Also eligible for annual stock option grants of 22,100 shares after each annual meeting starting 2025.","Board determined Dr. Hughes is independent under Nasdaq standards; serves as Class III director until 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-136042","json":"https://secwatch.observer/filing/0000950170-24-136042.json","markdown":"https://secwatch.observer/filing/0000950170-24-136042.md","text":"https://secwatch.observer/filing/0000950170-24-136042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/0000950170-24-136042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/glue-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:41:50.622246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}